Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.

MENU

Press Releases

April 9, 2018

Adapt Pharma® Welcomes Canadian & Ontario Governments Programs Providing NARCAN™ (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies...

April 5, 2018

ADAPT Pharma® Welcomes Surgeon General Naloxone Advisory Strengthens Partnerships to Expand NARCAN® (naloxone HCl) Nasal Spray Affordable Access and Awareness...

March 19, 2018

ADAPT Pharma® Expands Program Offering Free NARCAN® (naloxone HCl) Nasal Spray to Eligible Schools and Universities  ...

March 7, 2018

Ontario Government takes significant action to address opioid crisis; NARCAN™ Nasal Spray to be made available to all Ontarians free of charge through pharmacies...

March 5, 2018

Adapt Pharma Expands Technical and R&D Teams...

November 14, 2017

Wisconsin Attorney General & University of Wisconsin System Partner with Adapt Pharma® to Increase Access to NARCAN® (naloxone HCl) Nasal Spray...

November 3, 2017

Adapt Pharma® Presents Human Factors Study Data on Usability of NARCAN® (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abus...

October 17, 2017

Adapt Pharma® Launches Roll Call Training Video to Educate Law Enforcement on NARCAN® (naloxone HCI) Nasal Spray 4mg...

October 3, 2017

Adapt Pharma® Announces Partnership with New York to Provide NARCAN® (naloxone HCI) Nasal Spray 4mg...

July 5, 2017

Opioid Overdose Antidote NARCAN™ Nasal Spray Now Carried by Nearly 400 Organizations across Canada...

June 20, 2017

Adapt Pharma Acknowledges the U.S. Drug Enforcement Administration (DEA) New Guidance to First Responders on the Hazards of Exposure to Fentanyl...

June 12, 2017

Adapt Pharma Presents Human Factors Study Data at 2017 International Conference on Opioids....

June 6, 2017

Survey Data Published on Community Use of NARCAN® (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal...

June 6, 2017

Adapt Pharma Clarifies Confusion Between NARCAN™ Nasal Spray and Injectable Naloxone Emergency Opioid Treatments...

April 24, 2017

Emergency opioid treatment NARCAN™ Nasal Spray added to NIHB Program in Canada Registered First Nations and recognized Inuit now have access to additional naloxone treatment...

April 10, 2017

Adapt Pharma Expands Free NARCAN® Nasal Spray Program to U.S. Colleges and Universities...

March 16, 2017

New Data Presented on Adapt Pharma’s Community Use of Narcan® Nasal Spray 4 mg to Reverse Opioid-Related Overdose...

February 28, 2017

Adapt Pharma Marks One-Year Anniversary of NARCAN® Nasal Spray (naloxone HCl) 4mg Launch in the U.S....

February 21, 2017

Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray...

January 25, 2017

NARCAN® (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration (FDA)...

December 1, 2016

Adapt Pharma Partners with OH Attorney General DeWine to Guarantee Public Interest Price...

November 22, 2016

Adapt Pharma Welcomes U.S. Food and Drug Administration Consumer Update Regarding Opioids...

November 4, 2016

Reported shortage of non-FDA approved improvised nasal naloxone kits....

October 6, 2016

FDA Joint Meeting Endorses Commitment to Higher Doses and Broader Access for Naloxone to Help in Fight Against Opioid Overdose ...

October 5, 2016

Adapt Pharma Announces NARCAN® coverage with California’s Medi-Cal Program. Agreement Results in Restriction-Free, $0 Copay Access to NARCAN® Nasal Spray for Millions of Californians...

October 3, 2016

Health Canada Approves Adapt Pharma’s Naloxone Hydrochloride Nasal Spray to Treat Opioid Overdose...

September 20, 2016

Newly Published Study Finds NARCAN® Nasal Spray’s Concentrated Formulation Rapidly Delivers an Effective Naloxone Dose and is Readily Usable by the General Public...

July 12, 2016

Adapt Pharma to Launch Program to Raise Awareness, Expand Access and Facilitate Product Experience of NARCAN® (Naloxone HCl) Nasal Spray - a new Treatment for Opioid Overdose...

July 6, 2016

Canada to Make Available U.S. FDA-Approved Intranasal Naloxone Medication...

May 2, 2016

Adapt Pharma submits NDS to Health Canada for Naloxone Nasal Spray...

April 28, 2016

Adapt Pharma Teams with Smith Medical Partners to Support Distribution of Free NARCAN® (Naloxone HCl) Nasal Spray Offer to All U.S. High Schools...

April 14, 2016

Introducing the NARCAN® Now App, a smartphone application providing opioid overdose recognition education and treatment instructions...

April 11, 2016

Adapt Pharma Names Mike Kelly President of U.S. Operations. Contributing Over 25 Years of Pharmaceutical Expertise to Adapt Executive Team...

February 25, 2016

NARCAN® (Naloxone Hydrochloride) NASAL SPRAY Now Available in the United States for Emergency Treatment of Known or Suspected Opioid Overdose...

January 25, 2016

Adapt Pharma to offer all U.S. high schools a free NARCAN® Nasal Spray...

January 14, 2016

Adapt Pharma facilitates NARCAN® (naloxone hydrochloride) Nasal Spray access to state and local public entities...

November 19, 2015

NARCAN® (naloxone hydrochloride) Nasal Spray approved by U.S. food and drug administration...

September 24, 2015

FDA accepts for review Adapt Pharma’s NARCAN® (naloxone hydrochloride) Nasal Spray NDA...

July 27, 2015

Adapt Pharma submits NDA to FDA for NARCAN® (Naloxone) Nasal Spray...

July 2, 2015

Adapt Pharma acquires NARCAN NDA and obtains license to the NARCAN® trademark...

June 3, 2015

Adapt Pharma Commences Rolling NDA Submission to the FDA for Intranasal Naloxone...

April 22, 2015

Adapt Pharma Announces Successful Completion of Intranasal Naloxone Study...

February 17, 2015

Adapt Pharma Announces Fast Track Designation From FDA for Naloxone Nasal Spray...

January 5, 2015

Adapt Pharma and Profector Life Sciences Enter a Development and Investment Collaboration...

December 16, 2014

Adapt Pharma Announces License Agreement for Naloxone Nasal Spray With Lightlake Therapeutics Inc....

May 2, 2014

Adapt Pharma Completes $95 Million Equity Financing U.S. Focused Specialty Pharmaceutical Company...